Ann: Application for quotation of securities - CHM, page-15

the number of shares on issue is somewhat irrelevant. Market cap and enterprise value are much more important.

even after accounting for the recent placement, a market cap of circa $12m is very cheap for a clinical stage biotech with 3 phase 1b trials and 1 phase 1/2 trials.

now the allogenic NK platform is potentially best in class and has already produced multiple complete responses in AML and MDS cancers in a sample of 3 patients during dose escalation. I have seen companies awarded fast track designation by the FDA when 5 out of 59 patients with R/R AML have a CR. S

We also have CDH17 which if proven effective is targeting a AUD50bn gastric cancer market. This CART was developed at UPENN by the pioneers of CART with exceptional pre clinical results. It is the only CART in the clinic globally that is targeting CDH17, which means we have an effective monopoly on this tech. Furthermore, if we get early signals, FDA can approve us moving straight to phase 2 immediately.

So lots to like about this company….